What exactly changed in the ATAI analyst rating on March 10, 2026?

H.C. Wainwright **maintained a Buy** on March 10, 2026, so the ATAI analyst rating stayed steady. The note reiterated coverage but did not add a new price target, leaving prior expectations intact.

Did the maintained Buy include a new ATAI price target?

No. The StreetInsider report shows H.C. Wainwright reiterated Buy without publishing a new ATAI price target. Investors must rely on prior targets and fundamental updates.

How should investors interpret a maintained Buy in ATAI analyst rating?

A maintained Buy shows continued analyst confidence, not fresh upside proof. Investors should use the ATAI analyst rating alongside clinical progress and balance sheet health to decide holdings.

How does Meyka AI view ATAI after the maintained Buy?

Meyka AI rates ATAI with a **B**, reflecting benchmarks, sector performance, growth, key metrics, and analyst consensus. This complements the ATAI analyst rating, but is not financial advice.

Analyst Ratings

H.C. Wainwright Maintains Buy on ATAI Atai Beckley N.V Mar 2026

ByHuzaifa Zahoor March 11, 2026March 11, 2026

On March 10, 2026 H.C. Wainwright maintained a Buy on Atai Beckley N.V, shaping the ATAI analyst rating. The firm left its stance unchanged, and StreetInsider reported the reiteration as a maintenance action. Market data showed a 6.43% ($0.25) move tied to the update, though the StreetInsider note did not list a new price target. This maintained Buy keeps institutional confidence visible, while investors should weigh clinical progress and cash runway against biotech sector volatility.